
Medicare announced it will now pay for a new molecular tissue test for idiopathic pulmonary fibrosis, called the Envisia Genomic Classifier (Veracyte). The availability of the new assay reshuffles the algorithm for the diagnosis of IPF, forcing consideration of transbronchial biopsy in some patients. However, professional societies do not yet endorse its general use. The [… read more]